A subsequent trial confirmed that the presence of both low CRP and low S100A12 levels in patients with JIA was associated with a decreased risk of JIA flare post DMARD withdrawal by 38% over 12 months (based on a hazard ratio of 0.62; P = 0.0455) compared with patients from a large registry in whom DMARD withdrawal occurred without consideration of biomarker levels [34]. This evidence concerns the gene S100A12 and juvenile idiopathic arthritis.